CRISPR Therapeutics AG (CRSP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
In November 2023, Vertex announced that Casgevy, a gene editing medicine for two rare blood diseases developed with CRISPR Therapeutics, had earned its first regulatory green light in the U.K. It has ...
Researchers have uncovered a serious side effect of using the CRISPR-Cas gene scissors. A molecule designed to make the process more efficient destroys parts of the genome.